Supplementary Table 1 - Main characteristics of studies on oral tofacitinib and ruxolitinib for the treatment of alopecia areata

Name: Supplementary Table 1 - Main characteristics of studies on oral tofacitinib and ruxolitinib for the treatment of alopecia areata
Creator: Da-Ae Yu
Published: 2019-08-12T11:13:32.741Z
Keywords: Alopecia Areata

Yu, Da-Ae

doi:10.17632/zc8k7phcng.1

Supplementary Table 1 - Main characteristics of studies on oral tofacitinib and ruxolitinib for the treatment of alopecia areata

Published: 12 August 2019| Version 1 | DOI: 10.17632/zc8k7phcng.1

Contributor:

Da-Ae Yu

Description

Supplementary table for the publication by Yu DA et al. Oral Janus kinase inhibitors for the treatment of alopecia areata: a systematic review and meta-analysis. J Am Acad Dermatol 2019.

Supplementary Table 1 - Main characteristics of studies on oral tofacitinib and ruxolitinib for the treatment of alopecia areata

Description

Files

Categories

Licence